These results reveal that the prophylactic infusion of allogeneic CD8+ T cells that are reactive against peptides derived from CML-associated antigens is a safe and promising therapeutic strategy[67]. This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.